Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -29% Improvement Relative Risk ICU admission 94% Discharge 78% c19early.org/q Onal et al. NCT04377789 Quercetin RCT LATE TREATMENT Is late treatment with quercetin+bromelain and vitamin C beneficial for COVID-19? RCT 429 patients in Turkey Higher mortality (p=0.57) and lower ICU admission (p=0.39), not stat. sig. Onal et al., Turk. J. Biol., 45:518-529 Favors quercetin Favors control
Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial
Onal et al., Turk. J. Biol., 45:518-529 (date from earlier preprint), NCT04377789 (history)
Onal et al., Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial, Turk. J. Biol., 45:518-529 (date from earlier preprint), NCT04377789
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 447 moderate-to-severe hospitalized patients in Turkey, 52 treated with quercetin, bromelain, and vitamin C, showing no statistically significant difference in clinical outcomes. NCT04377789 (history).
risk of death, 29.3% higher, RR 1.29, p = 0.57, treatment 1 of 49 (2.0%), control 6 of 380 (1.6%).
risk of ICU admission, 94.0% lower, RR 0.06, p = 0.39, treatment 0 of 49 (0.0%), control 14 of 380 (3.7%), NNT 27, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no hospital discharge, 77.8% lower, RR 0.22, p = 0.10, treatment 1 of 49 (2.0%), control 35 of 380 (9.2%), NNT 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Onal et al., 19 Jan 2021, Randomized Controlled Trial, Turkey, peer-reviewed, 10 authors, this trial uses multiple treatments in the treatment arm (combined with bromelain and vitamin C) - results of individual treatments may vary, trial NCT04377789 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: Turkish Journal of Biology Turk J Biol (2021) 45: 518-529 © TÜBİTAK doi:10.3906/biy-2104-16 http://journals.tubitak.gov.tr/biology/ Research Article Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial 1, 1 1 1 2 Hasan ÖNAL *, Bengü ARSLAN , Nurcan ÜÇÜNCÜ ERGUN , Şeyma TOPUZ , Seda YILMAZ SEMERCİ , 1 1 3 4 3 Mehmet Eren KURNAZ , Yulet Miray MOLU , Mehmet Abdussamet BOZKURT , Nurettin SÜNER , Ali KOCATAŞ  1 Department of Pediatric Nutrition and Metabolism Clinics, İstanbul Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey 2 Department of Neonatology, İstanbul Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey 3 Department of General Surgery, İstanbul Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey 4 Department of General Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, İstanbul, Turkey Received: 06.04.2021 Accepted/Published Online: 02.07.2021 Final Version: 30.08.2021 Abstract: Scientific research continues on new preventive and therapeutic strategies against severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). So far, there is no proven curative treatment, and a valid alternative therapeutic approach needs to be developed. This study is designed to evaluate the effect of quercetin in COVID-19 treatment. This was a single-centre, prospective randomized controlled cohort study. Routine care versus QCB (quercetin, vitamin C, bromelain) supplementation was compared between 429 patients with at least one chronic disease and moderate-to-severe respiratory symptoms. Demographic features, signs, laboratory results and drug administration data of patients were recorded. The endpoint was that QCB supplementation was continued throughout the follow-up period from study baseline to discharge, intubation, or death. The most common complaints at the time of hospital admission were fatigue (62.4%), cough (61.1%), anorexia (57%), thirst (53.7%), respiratory distress (51%) and chills (48.3%). The decrease in CRP and ferritin levels was higher in the QCB group (all Ps were < 0.05). In the QCB group, the increase in platelet and lymphocyte counts was higher (all Ps were < 0.05). QCB did not reduce the risk of events during follow-up. Adjustments for statistically significant parameters, including the lung stage, use of favipiravir and presence of comorbidity did not change the results. While there was no difference between the groups in terms of event frequency, the QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. While there was no difference between the groups in terms of event frequency, QCB supplement group had more advanced pulmonar findings, and QCB supplement is shown to have a positive effect on laboratory recovery/results. Therefore, we conclude that further studies involving different doses and plasma level measurements are required to reveal the dose/response relationship and bioavailability of QCB for a better understanding of the role of QCB in the treatment of SARS CoV-2. Key words: Bromelain, COVID-19, quercetin, vitamin C
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit